SAN DIEGO, Dec. 21, 2016 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused
on neurological and endocrine related disorders, announced today
that Timothy P. Coughlin will be
stepping down from his position as Chief Financial Officer in
mid-February for personal reasons. The Board has initiated a
replacement search and Mr. Coughlin has agreed to continue with the
Company through 2017 to facilitate a smooth transition of
responsibilities.
"On behalf of the board, shareholders and our employees, I want
to thank Tim for his over ten years of tireless service as CFO of
Neurocrine," said Dr. Kevin C.
Gorman, President and Chief Executive Officer of Neurocrine.
"Tim has been a tremendous person to work with and a key part of
the team, which orchestrated the turnaround of Neurocrine. I am
very pleased that we will continue to work together through a
transition period. Through his leadership we are in a strong
financial position that allows us to continue to execute on
our commercialization and clinical plans."
"Deciding to leave Neurocrine was an extremely difficult
decision for me. I am incredibly proud of the biotechnology company
we have built and the promising therapies the Company has and
continues to develop," said Mr. Coughlin. "I look forward to
working through transitioning to a new CFO, as well as the next
evolution of Neurocrine."
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two programs are elagolix, a gonadotropin-releasing
hormone antagonist in Phase III development for women's health that
is partnered with AbbVie Inc., and INGREZZA, a vesicular monoamine
transporter 2 inhibitor for which an NDA has been filed with the
FDA for the treatment of tardive dyskinesia, and is in Phase II
development for patients with Tourette syndrome. Neurocrine plans
to commercialize INGREZZA in the United
States upon approval of the NDA by the FDA.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
In addition to historical facts, this press release may
contain forward-looking statements that involve a number of risks
and uncertainties. Among the factors that could cause actual
results to differ materially from those indicated in the
forward-looking statements are risks and uncertainties associated
with Neurocrine's business and finances in general, INGREZZA
development and commercialization, the Company's R & D pipeline
and the Company overall. Specifically, the risks and uncertainties
the Company faces include risks that the Company's product
candidates may not obtain regulatory approval or that the U.S. Food
and Drug Administration or regulatory authorities outside the U.S.
may make adverse decisions regarding the Company's product
candidates; risks that clinical development activities may not be
completed on time or at all; risks that clinical development
activities may be delayed for regulatory or other reasons, may not
be successful or replicate previous clinical trial results, may
fail to demonstrate that our product candidates are safe and
effective, or may not be predictive of real-world results or of
results in subsequent clinical trials; risks that the Company's
product candidates may be precluded from commercialization by the
proprietary rights of third parties, or have unintended side
effects, adverse reactions or incidents of misuse; risks associated
with the Company's dependence on third parties for development,
manufacturing and marketing activities; risks that the Company's
research programs will not identify pre-clinical candidates for
further development; risks that the Company will be unable to
raise additional funding required to complete development of all of
its product candidates; risk and uncertainties relating to
competitive products and technological changes that may limit
demand for the Company's products; and other risks described in the
Company's quarterly report on Form 10-Q for the quarter ended
September 30, 2016. Neurocrine
disclaims any obligation to update the statements contained in this
press release after the date hereof.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-chief-financial-officer-timothy-p-coughlin-to-step-down-300382314.html
SOURCE Neurocrine Biosciences, Inc.